TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Oncopeptides AB
Closing information (x1000 EUR)
Closing information | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Turnover | 751 | 11,567 | 0 |
Financial expenses | 79 | 93 | 148 |
Earnings before taxes | -30,344 | -138,984 | -158,649 |
EBITDA | -29,849 | -136,850 | -157,097 |
Total assets | 34,626 | 42,963 | 94,322 |
Current assets | 32,712 | 40,322 | 89,146 |
Current liabilities | 7,474 | 22,025 | 30,605 |
Equity capital | 26,445 | 20,619 | 57,474 |
- share capital | 942 | 818 | 616 |
Employees (average) | 57 | 229 | 182 |
Financial ratios
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Solvency | 76.4% | 48.0% | 60.9% |
Turnover per employee | 13 | 51 | 0 |
Profit as a percentage of turnover | -4040.5% | -1201.6% | |
Return on assets (ROA) | -87.4% | -323.3% | -168.0% |
Current ratio | 437.7% | 183.1% | 291.3% |
Return on equity (ROE) | -114.7% | -674.1% | -276.0% |
Change turnover | -9,879 | 11,567 | 0 |
Change turnover % | -93% | ||
Chg. No. of employees | -172 | 47 | 145 |
Chg. No. of employees % | -75% | 26% | 392% |
Total value of public sale
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Total value of public sale | 0 | 0 | 0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.